Compugen (CGEN) Cost of Revenue (2010 - 2026)
Compugen (CGEN) posted quarterly Cost of Revenue of $1.8 million for Q1 2026, down 24.0% year-over-year from $2.4 million in Q1 2025, and down 48.42% on a QoQ basis from $3.5 million in Q4 2025.
Analysis
Compugen (CGEN) Cost of Revenue (2010 - 2026) Analysis & Trends
Compugen has reported Cost of Revenue for 14 years, with the latest figure at $1.8 million in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $1.8 million, down 24.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (up 5.43% YoY), and the FY2025 annual result was $9.3 million, up 16.66% from the prior year.
- Cost of Revenue fell to $1.8 million in Q1 2026, from $3.5 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $3.6 million in Q3 2024 and troughed at $675000.0 in Q4 2024.
- A 5-year average of $2.0 million and a median of $1.8 million in 2026 frame the typical range for Cost of Revenue.
- The widest annual swing landed in 2024, when Cost of Revenue slumped 66.32%; it then soared 423.85% in 2025.
- A 5-year view of Cost of Revenue shows it stood at $975000.0 in 2022, then jumped by 105.54% to $2.0 million in 2023, then slumped by 66.32% to $675000.0 in 2024, then soared by 423.85% to $3.5 million in 2025, then slumped by 48.42% to $1.8 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $1.8 million in Q1 2026, $3.5 million in Q4 2025, and $1.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Compugen | 241.97 Mn | 156.35 Mn | -92,000.00 | 2.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.69 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | 3.54 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Sep 30, 2021 | 680,000.00 |
| Sep 30, 2018 | 684,000.00 |
| Mar 31, 2018 | 350,000.00 |
| Dec 31, 2016 | 35,000.00 |
| Sep 30, 2016 | 21,000.00 |
| Jun 30, 2016 | 86,000.00 |
| Mar 31, 2016 | 81,000.00 |
| Dec 31, 2015 | 1.04 Mn |
| Sep 30, 2015 | 201,000.00 |
| Jun 30, 2015 | 148,000.00 |